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Table 1 Baseline Characteristics
Demographic
Very Elderly
(n ¼ 73)
Nonelderly
(n ¼ 82) p Value
Age (yrs) 78.9  2.98 56.3  5.18
Males (%) 54 (74.0) 65 (79.3) 0.436*
Race 0.236*
Caucasian (%) 69 (94.5) 72 (87.8)
Black or African
American
4 (5.5) 8 (9.8)
Multiracial (%) 0 2 (2.4)
Height (cm) 173.0 (8.21) 173.4 (9.27) 0.780y
Weight (kg) 85.4 (11.19) 93.1 (18.63) 0.002y
Body mass index
(kg/m2)
28.5  3.41 31.0  5.88 0.002y
No. with risk factors/
medical history
Current smoker [yes] (%) 5 (6.8) 24 (29.3) <0.001*
Systolic blood
pressure (mm Hg)
140.7 (18.33) 130.9 (17.44) <0.001y
Hypertension (%) 52 (71.2) 57 (69.5) 0.815*
Hyperlipidemia (%) 60 (82.2) 72 (87.8) 0.326*
Diabetes [yes] (%) 20 (27.4) 15 (18.3) 0.176*
Prior CABG [yes] (%) 18 (24.7) 13 (15.9) 0.210*
Prior MI [yes] (%) 52 (71.2) 54 (65.9) 0.472*
Prior PCI [yes] (%) 56 (76.7) 67 (81.7) 0.443*
No. with co-medications
ACE/ARB (%) 52 (71.2) 59 (72.0) 0.921*
Diuretics (%) 16 (21.9) 19 (23.2) 0.852*
Proton pump
inhibitors (%)
22 (30.1) 20 (24.4) 0.422*
Calcium channel 25 (34.2) 19 (23.2) 0.127*
Abbreviations
and Acronyms
AUC(0-tlast) = area under the
concentration-time curve,
time 0 to last quantiﬁable
concentration 4 h
post-dose
CAD = coronary artery
disease
HPR = high on-treatment
platelet reactivity
LTA = light transmission
aggregometry
MD = maintenance dose
MPA = maximum platelet
aggregation
NE = nonelderly
(45 to <65 years of age)
PD = pharmacodynamic
PK = pharmacokinetic
RPA = residual platelet
aggregation
VASP-PRI = vasodilator-
associated stimulated
phosphoprotein platelet
reactivity index
VE = very elderly
(75 years of age)
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578The TRITON–TIMI 38 (TRial
to Assess Improvement in
Therapeutic Outcomes by Opti-
mizing Platelet InhibitioN with
Prasugrel–Thrombolysis In Myo-
cardial Infarction 38) study dem-
onstrated signiﬁcantly reduced
rates of the composite efﬁcacy
endpoint of cardiovascular death,
myocardial infarction, or stroke
for prasugrel versus clopidogrel
in patients with acute coronary
syndrome (ACS) undergoing per-
cutaneous coronary intervention
(1). However, risk of major bleed-
ing events was increased in very
elderly (VE) patients receiving the
prasugrel 10-mg maintenance
dose (MD).
A prasugrel 5-mg MD should
reduce bleeding risk, based on
population pharmacokinetic (PK)
substudy modeling in TRITON–
TIMI 38 (2), which predicted
active metabolite exposures with
prasugrel 5 mg in VE patients,
similar to the lowest exposure
quartile in TRITON patients,blockers (%)
Beta-blockers (%) 59 (80.8) 64 (78.0) 0.670*
Lipid-modifying
agents (%)
69 (94.5) 73 (89.0) 0.218*
Values are mean  SD or n (%). Assessed via *Pearson chi-square test and y2-sample t-test.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CABG ¼ coronary
artery bypass graft; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.where efﬁcacy was maintained but bleeding risk was lower
(2,3). However, direct clinical, pharmacodynamic (PD), and
PK data to support the potential use of prasugrel 5-mg MD
in VE patients are limited. We therefore designed the
GENERATIONS (Comparison of Prasugrel and Clopi-
dogrel in Very Elderly and Non-Elderly Patients With Stable
Coronary Artery Disease) trial to test, in aspirin-treated
patients with stable coronary artery disease (CAD), whether
prasugrel 5 mg in VE patients would meet pre-speciﬁed
antiplatelet noninferiority criteria versus prasugrel 10 mg in
nonelderly (NE) (45 to <65 years of age) patients. Thend Company, and Merck; and honoraria from
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Figure 1 Platelet Reactivity Including Primary Endpoint
Boxes represent 25th to 75th percentiles (line ¼ median); whiskers are 10th to
90th percentiles. ADP ¼ adenosine diphosphate; BL ¼ baseline; Clop ¼ clopi-
dogrel; MPA ¼ maximum platelet aggregation; Pras ¼ prasugrel.
Figure 2
Comparison of Prasugrel 5 mg in Very Elderly Patients and Prasugrel 10 mg in Nonelderly Patients by
Alternative Pharmacodynamic Measures and Parameters
Dotted line indicates high on-treatment platelet reactivity (HPR) criterion; boxes and whiskers are as speciﬁed in Figure 1. IPA ¼ inhibition of platelet aggregation; PRU ¼ P2Y12
reactivity units; VASP-PRI ¼ vasodilator-associated stimulated phosphoprotein phosphoprotein platelet reactivity index; other abbreviations as in Figure 1.
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579approved clopidogrel 75-mg MD was also assessed versus
prasugrel 5 mg and 10 mg.Methods
The GENERATIONS trial was an international Phase 1b
trial. A detailed description of the trial design (Online
Fig. 1; similar to the FEATHER study [4]) and
methods is provided in the Online Appendix. Brieﬂy, anaspirin run-in was followed by a baseline/randomization
visit, then 3 crossover treatment periods (12  2 days
each). During treatment period 1 (single-blinded), all VE
patients received prasugrel 5 mg and NE patients received
prasugrel 10 mg. During periods 2 and 3 (double-blinded),
VE patients received either prasugrel 10 mg (period 2)
then clopidogrel 75 mg (period 3) or the reverse; NE
patients received prasugrel 5 mg and then clopidogrel 75 mg
or the reverse.
Table 2
High On-Treatment Platelet Reactivityin Very Elderly and Nonelderly Patients Treated With
Prasugrel (5 mg or 10 mg) or Clopidogrel (75 mg)
Measure
Very Elderly Nonelderly
Prasugrel 5 mg
(n ¼ 72)
Prasugrel 10 mg
(n ¼ 70)
Clopidogrel 75 mg
(n ¼ 71)
Prasugrel 5 mg
(n ¼ 78)
Prasugrel 10 mg
(n ¼ 79)
Clopidogrel 75 mg
(n ¼ 79)
MPA to 20 mM ADP >50% 53 (74.6) 19 (27.1) 60 (85.7) 62 (79.5) 24 (30.4) 60 (75.9)
Prasugrel 5 mg vs. prasugrel 10 mg <0.001 <0.001
Prasugrel 5 mg vs. clopidogrel 75 mg 0.025 0.562
Prasugrel 10 mg vs. clopidogrel 75 mg <0.001 <0.001
IPA to 20 mM ADP <20% 23 (32.4) 1 (1.4) 37 (52.9) 31 (39.7) 7 (8.9) 38 (48.1)
Prasugrel 5 mg vs. prasugrel 10 mg <0.001 <0.001
Prasugrel 5 mg vs. clopidogrel 75 mg 0.001 0.177
Prasugrel 10 mg vs. clopidogrel 75 mg <0.001 <0.001
VerifyNow P2Y12 PRU >235 10 (14.1) 0 28 (40.6) 17 (22.1) 0 18 (22.8)
Prasugrel 5 mg vs. prasugrel 10 mg NE NE
Prasugrel 5 mg vs. clopidogrel 75 mg <0.001 0.805
Prasugrel 10 mg vs. clopidogrel 75 mg NE NE
VASP-PRI 50% 29 (43.3) 2 (3.1) 41 (61.2) 45 (61.6) 7 (9.5) 48 (65.8)
Prasugrel 5 mg vs. prasugrel 10 mg <0.001 <0.001
Prasugrel 5 mg vs. clopidogrel 75 mg 0.007 0.462
Prasugrel 10 mg vs. clopidogrel 75 mg <0.001 <0.001
Values are n (%).
ADP ¼ adenosine diphosphate; IPA ¼ inhibition of platelet aggregation; MPA ¼ maximum platelet aggregation; NE ¼ not evaluable; PRI ¼ platelet reactivity index; PRU ¼ P2Y12 reactivity units; VASP-
PRI ¼ vasodilator-associated stimulated phosphoprotein platelet reactivity index.
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580The protocol was approved by local investigational
review boards and performed in compliance with good clinical
practice and theDeclaration ofHelsinki.All patients provided
signed informed consent prior to any study procedure.
The primary objective was a noninferiority analysis
of maximum platelet aggregation (MPA) to 20 mMadenosine
diphosphate (ADP) by light transmission aggregometry
(LTA), comparing the median for prasugrel 5 mg in
VE patients versus the 75th percentile for prasugrel 10 mg
inNEpatients (Online Fig. 2). This value reﬂected the goal of
reducing PD effect in VE to the lower range of PD effect for
prasugrel 10 mg in NE. The upper limit of the 1-sided 97.5%
conﬁdence interval (CI) of the difference was compared with
the pre-speciﬁed, noninferiority margin of 15 percentage
points (Online Appendix). The primary analysis had >80%
power at a 1-sided 2.5% signiﬁcance level.
Between-age cohort comparisons of PD response used
analysis of covariance, and comparison of high on-treatment
platelet reactivity (HPR) used Fisher exact test.Results
Patient characteristics. Among randomized patients (N ¼
155) (Online Fig. 3), most had a history of myocardial
infarction (68.4%), hypertension (70.3%), and/or hyperlip-
idemia (85.2%); 22.6% had diabetes (Table 1). Mean ages
were 78.9 (VE) and 56.3 (NE) years old. At screening, VE
(versus NE) had signiﬁcantly lower mean weight and body
mass index, higher mean systolic blood pressure, and a lower
percentage currently used tobacco (Table 1) (all p < 0.05).
The 2 cohorts were otherwise well matched.
PD parameters. Platelet reactivity at baseline was compa-
rable between age cohorts according to LTA measurementsand vasodilator-associated stimulated phosphoprotein
platelet reactivity index (VASP-PRI) but signiﬁcantly
greater in VE for VerifyNow P2Y12 (Accumetrics Inc., San
Diego, California) (VN-P2Y12; p< 0.005) (Online Table 1).
Median MPA response to prasugrel 5 mg in VE (58.0%)
was noninferior to the 75th percentile of MPA response to
prasugrel 10 mg in NE (52.0%; difference, 6.0% [95% CI:
1.0% to 9.0%]), as the upper boundary of the CI was 9.0%,
below the pre-speciﬁed 15% margin (Fig. 1). Nonetheless,
antiplatelet effect was signiﬁcantly lower with prasugrel 5 mg
in VE than 10 mg in NE, based on higher mean MPA to 20
mM ADP (LS [least squares] mean difference, 91.4% [95%
CI: 5.4% to 13.3%]) and other aggregation measures (all
p < 0.001) (Fig. 2) and signiﬁcantly greater HPR rates (all
p <0.001) (Table 2). Comparing prasugrel 5 mg and clopi-
dogrel 75 mg in VE, antiplatelet effect was greater with
prasugrel 5 mg based on signiﬁcantly lower MPA to 20 mM
ADP (LSmean difference: 5.7% [95% CI: 8.4%
to 3.0%]) and other measures (all p < 0.001) (Fig. 3) and
lower HPR rates (all measures p < 0.05) (Fig. 4). In NE
patients, prasugrel 10 mg further reduced aggregation
response (MPA to 20 mMADP LSmean difference: 13.3%
[95% CI: 16.1% to 10.5%]) and HPR rates (Table 2)
versus clopidogrel 75 mg.
In a comparison of age groups, PD responses during
treatment were generally similar (Online Table 1, Fig. 1),
except for greater platelet inhibition in VE patients by
VASP-PRI, with both prasugrel doses (p < 0.05) and
reduced inhibition in VE patients by VN-P2Y12 with clo-
pidogrel 75 mg (p ¼ 0.011).
Pharmacokinetics. For each treatment, active metabolite
exposures (Fig. 5) were slightly greater in VE than in NE
patients; the difference in area under the concentration-time
Figure 3
Platelet Response to 75 mg Clopidogrel and 5 mg Prasugrel Administration in Very Elderly Patients by
Alternative Pharmcodynamics Measures and Parameters
Dotted line indicates high on-treatment platelet reactivity criterion. Boxes and whiskers are as speciﬁed in Figure 1 legend. Signiﬁcance was assessed using a mixed-effect
model with repeated measures analysis. Abbreviations as in Figure 2.
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581curve, time 0 to last quantiﬁable concentration (AUC(0-tlast)
for prasugrel 10 mg was 12% (41.2 vs. 36.7 ng/h/ml) and
17% for 5 mg (18.9 vs. 16.1 ng/h/ml, respectively). For VE
receiving prasugrel 5 mg relative to NE receiving prasugrel
10 mg, the ratio of geometric means of AUC(0-tlast) was
51%. Active metabolite exposures were higher for prasugrel
5 mg than for clopidogrel 75 mg in each age cohort.
Safety and tolerability. Bleeding-related adverse event
rates were similar between age groups (Table 3); most
events were mild contusions and/or hematomas and werenot clinically signiﬁcant. Between treatments, rates of
bleeding events with prasugrel 5 mg and clopidogrel 75 mg
were similar and signiﬁcantly lower than prasugrel 10 mg
(see the Online Appendix for additional safety results).Discussion
In this PK/PD study in stable CAD patients receiving
aspirin, MPA for prasugrel 5 mg in VE met noninferiority
criterion versus prasugrel 10 mg in NE patients.
Figure 4
Percentage of Very Elderly Patients With
High On-Treatment Platelet Reactivity
(A)MPA to 20 mM ADP >50%; (B) VN-P2Y12 PRU >235; and (C) VASP PRI 50%.
Signiﬁcance was assessed using a generalized linear model with repeated
measures. HPR ¼ high on-treatment platelet reactivity; VE ¼ very elderly; other
abbreviations as in Figure 2.
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582Furthermore, in VE patients, platelet inhibition was
signiﬁcantly greater for prasugrel 5 mg than for clopidogrel
75 mg, while rates of bleeding events (mainly mild bruising)
were similar between prasugrel 5 mg and clopidogrel 75 mg
and were lower than prasugrel 10 mg.
Although the current study met the primary PD non-
inferiority endpoint, platelet inhibition was signiﬁcantly
lower and HPR rates were signiﬁcantly higher for prasugrel
5 mg in VE than prasugrel 10 mg in NE patients. This
agrees with prior modeling (2) and reﬂects an expected
reduction in PD effect intended to reduce bleeding risk in
VE patients (1). The PK of prasugrel active metaboliteFigure 5
Active Metabolite Exposure Following Prasugrel and
Clopidogrel Treatments in Very Elderly and
Nonelderly Patients
Boxes and whiskers are as speciﬁed in Figure 1. AUC ¼ area under the concen-
tration curve; other abbreviations as in Figure 1.(Pras-AM) has been assessed in elderly individuals in
2 previous studies. One study found no signiﬁcant difference
in exposure between healthy elderly subjects (65 to 80 years
of age) and younger (20 to 39 years of age) during prasugrel
5 mg and 10 mg (with background aspirin) (5). In the
TRITON–TIMI 38 study, VE patients had higher exposure
than patients <75 years of age, although differences were
largely explained by body weight (3). In the current study,
prasugrel 5 mg resulted in w50% lower Pras-AM concen-
trations than prasugrel 10 mg within age cohorts, with only
slightly higher Pras-AM exposure in VE than in NE
patients, likely reﬂecting body weight differences (4).
PD response did not generally differ between age groups.
This contrasts somewhat with ﬁndings of reduced (clopi-
dogrel) or borderline reduced (prasugrel) antiplatelet effect
in VE patients in the SENIOR-PLATELET observational
study (6); however, there were major baseline clinical
differences between cohorts in that study. Our ﬁndings are
consistent with a meta-analysis of randomized, controlled,
phase I/II studies, which found no age-dependent differ-
ences (7).
If used in VE patients, the prasugrel 5-mg MD is rec-
ommended in European labeling (8). Across measurements
in this study, prasugrel 5 mg reduced platelet reactivity
signiﬁcantly versus clopidogrel 75 mg, with lower HPR
rates. This is consistent with the previously reported increase
in platelet inhibition observed for VE clopidogrel poor
responders following a switch to prasugrel 5 mg (9), greater
antiplatelet effects in VE ACS/percutaneous coronary
intervention (PCI) patients with HPR on standard clopi-
dogrel therapy, when switched to prasugrel 5-mg versus
double-dose clopidogrel (150 mg) (10); and greater platelet
inhibition versus clopidogrel 75 mg with prasugrel 10 mg
or 5 mg (in VE and patients <60 kg) in the TRILOGY
ACS study in medically treated patients (11). However, in
TRILOGY ACS, no signiﬁcant differences were seen
between treatments in the primary clinical endpoint (12).
One interpretation has been that in medically treated,
nonstented patients, further platelet inhibition does not
provide additional beneﬁt, which is in contrast to a previous
study in PCI-treated patients (TRITON) (1).
This study was not designed to assess clinical outcomes;
however, we observed no major drug-related bleeding events,
but relatively frequent minor contusions, hematomas, or
epistaxis-related bleeding events. Prasugrel 5-mg treatment
resulted in a bleeding event rate lower versus prasugrel 10 mg
and similar to clopidogrel-treated patients.
Study limitations. This study was limited in that, as a PK/
PD study, duration was limited, and it was not intended to
assess clinical outcomes. Dosing for some age and treatment
comparisons occurred in separate periods due to the cross-
over design. In addition, VE patients had lower mean body
weight and body mass index despite entry criteria requiring
body weight >60 kg; also, fewer subjects were smokers
versus NE patients, factors which could potentially have
impacted platelet responses somewhat.
Table 3
Bleeding Events Related to Study Drug in Very Elderly and Nonelderly Patients With Stable Coronary Artery Disease
Treated With 5-mg Prasugrel, 10-mg Prasugrel, and 75-mg Clopidogrel
Drug-Related Bleeding
Adverse Events*
Very Elderly Nonelderly
Prasugrel 5 mg
(n ¼ 73)
Prasugrel 10 mg
(n ¼ 71)
Clopidogrel 75 mg
(n ¼ 72)
Prasugrel 5 mg
(n ¼ 79)
Prasugrel 10 mg
(n ¼ 82)
Clopidogrel 75 mg
(n ¼ 79)
Mild 9, 11 (12.3) 21, 35 (29.6) 9, 18 (12.5) 11, 12 (13.9) 24, 32 (29.3) 10, 12 (12.7)
Contusion 4, 5 (5.5) 9, 12 (12.7) 4, 8 (5.6) 1, 1 (1.3) 6, 6 (7.3) 3, 3 (3.8)
Hematoma 1, 1 (1.4) 9, 10 (12.7) 2, 4 (2.8) 5, 6 (6.3) 9, 12 (11.0) 3, 5 (3.8)
Epistaxis 2, 2 (2.7) 0 (0) 0 (0) 1, 1 (1.3) 4,4 (4.9) 1, 1 (1.3)
Ecchymosis 1, 1 (1.4) 2, 5 (2.8) 1, 1 (1.4) 2, 2 (2.5) 4, 6 (4.9) 3, 3 (3.8)
Hematuria 0 (0) 2, 6 (2.8) 1, 1 (1.4) 0 (0) 0 (0) 0 (0)
Other 2, 2 (2.7) 2, 2 (2.8) 2, 4 (2.8) 2, 2 (2.5) 3, 4 (3.7) 0 (0)
Moderate 1, 1 (1.4) 1, 1 (1.4) 0 (0) 0 (0) 0 (0) 0 (0)
Ecchymosis 1, 1 (1.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Melaena 0 (0) 1, 1 (1.4) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 1, 1 (1.4) 0 (0) 0 (0) 0 (0)
More severe than baseline,y 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1, 1 (1.3)
Values are N, n (%). *N is the count of patients, n is the count of events. Percentages are based on the number of patients in the randomized safety population. Patients were counted more than once if the
patient had events in more than one severity category. yMore severe than baseline indicates an increase in categorical severity for an event present at baseline.
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583Conclusions
In summary, PD response to prasugrel 5 mg in VE patients
met the noninferiority criterion of the primary comparison to
prasugrel 10 mg in NE patients, but platelet inhibition was
signiﬁcantly lower. Prasugrel 5 mg generated greater active
metabolite exposure and antiplatelet PD effect than clopi-
dogrel 75 mg in VE patients, with lower HPR rates, while
minor bleeding rates for prasugrel 5 mg were lower than
prasugrel 10 mg and similar to clopidogrel-treated patients.
These results suggest that maintenance dosing with prasugrel
5 mg compared to prasugrel 10 mg could provide better risk-
beneﬁt balance for VE ACS patients with lower rates of
HPR and a similar bleeding risk compared to clopidogrel 75
mg. Additional randomized, controlled clinical trials are
necessary to verify the clinical relevance of these results,
particularly in ACS patients undergoing PCI.
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